DEAR DR. ROACH: Could you please advise what the current recommendation is as far as follow-up colonoscopies are concerned? It has always been my understanding from what I have read that virtually all ...
A new study published in the journal Gastroenterology supports the guidelines suggesting patients ages 50 and older at low risk of colon cancer should receive a screening colonoscopy every 10 years ...
The recent death of the 48-year-old actor James Van Der Beek is again highlighting how colorectal cancer is increasingly ...
Data on colorectal cancer (CRC) screening gathered over the past decade have prompted the American College of Gastroenterology (ACG) to update its guidelines, last issued in 2009. The new ...
The American Gastroenterological Association (AGA) released a new clinical guideline making no recommendation—for or against—the use of computer-aided detection systems (CADe) in colonoscopy. A ...
It’s the fourth most common cancer in the U.S., and a recent study showed colon cancer is on the rise in younger adults. The American Cancer Society recommends adults at average risk start regular ...
Colonoscopy billing can be very complex, hinging on distinctions between screening and diagnostic intent. A single ICD-10 code, CPT selection or missing modifier can shift a procedure from fully ...
NEW YORK (Reuters Health) - UK guidelines for colon cancer surveillance might be better at catching pre-cancerous polyps early on than U.S. ones, a new study suggests. Because the UK guidelines ...
Dear Doctor: Can you please explain why we keep hearing different things about when to get screened for colon cancer? I think it just changed again, and it’s kind of confusing. I’m 47 years old and ...
Share on Pinterest Blood tests could be used more in the future in Crohn’s disease management. Bisual Studio/Stocksy More than half a million people in the United States live with Crohn’s disease. New ...
Family physicians' colonoscopy rates decreased from 11.32% in 2016 to 6.73% in 2021, influenced by patient demographics and financial factors. TAS-102 plus bevacizumab is cost-effective in China but ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results